Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report) was the recipient of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 12,280,000 shares, a drop of 16.1% from the July 31st total of 14,630,000 shares. Based on an average daily volume of 2,250,000 shares, the short-interest ratio is presently 5.5 days.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on CTXR shares. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Citius Pharmaceuticals in a report on Friday, May 31st. EF Hutton Acquisition Co. I raised shares of Citius Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 15th.
Get Our Latest Report on Citius Pharmaceuticals
Institutional Trading of Citius Pharmaceuticals
Citius Pharmaceuticals Trading Up 0.6 %
CTXR traded up $0.00 on Monday, reaching $0.57. The stock had a trading volume of 310,000 shares, compared to its average volume of 1,553,692. Citius Pharmaceuticals has a 12-month low of $0.48 and a 12-month high of $1.07. The business’s 50-day moving average price is $0.72 and its two-hundred day moving average price is $0.73. The company has a market cap of $103.02 million, a P/E ratio of -2.37 and a beta of 1.67.
Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). As a group, analysts predict that Citius Pharmaceuticals will post -0.21 earnings per share for the current year.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
Recommended Stories
- Five stocks we like better than Citius Pharmaceuticals
- How to Invest in Insurance Companies: A Guide
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- CD Calculator: Certificate of Deposit Calculator
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- How to Buy Cheap Stocks Step by Step
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.